Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis

Table 1 Year of regulatory approval in Italy of antiretroviral drugs, 1987-2008

Year	NRTI	NNRTI	PI	EI	II
1987	Zidovudine (AZT)
1992	Didanosine
1995	Zalcitabine
1996	Stavudine Lamivudine (3TC)		Indinavir Ritonavir Saquinavir HG
1998	AZT/3TC Co-formulation	Nevirapine	Nelfinavir
1999	Abacavir (ABC)	Efavirenz	Saquinavir SG
2001	ABC/AZT/3TC Co-formulation		Amprenavir Lopinavir/Ritonavir
2002	Tenofovir (TDF)
2004			Atazanavir	Enfuvirtide
2005	Emtricitabine (FTC) TDF/FTC Co-formulation ABC/3TC Co-formulation		Fosamprenavir Tripanavir
2007			Darunavir^a
2008				Maraviroc^a	Raltegravir^a
Not approved		Delavirdine Atevirdine DP 083

NRTI = Nucleoside Reverse Transcriptase Inhibitor; NNRTI = Non-nucleoside Reverse Transcriptase Inhibitor; PI = protease inhibitors; EI = Entry
and Fusion Inhibitors; II = Integrase Inhibitor
^a Not used in the IcoNa cohort prior to regulatory approval

ISSN: 1472-6963